TCGA-G2-A2EK-01A-22R-A18C-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.93298292
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.380
- BILE_ACID_METABOLISM+0.280
- APICAL_SURFACE+0.230
- COAGULATION+0.200
- ESTROGEN_RESPONSE_EARLY+0.190
- MYOGENESIS+0.180
- PANCREAS_BETA_CELLS+0.160
- KRAS_SIGNALING_UP+0.140
- ESTROGEN_RESPONSE_LATE+0.100
- XENOBIOTIC_METABOLISM+0.070
Top 10 suppressed
- E2F_TARGETS-0.650
- MYC_TARGETS_V1-0.630
- MYC_TARGETS_V2-0.630
- G2M_CHECKPOINT-0.620
- MTORC1_SIGNALING-0.530
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.530
- DNA_REPAIR-0.510
- OXIDATIVE_PHOSPHORYLATION-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.490
- MITOTIC_SPINDLE-0.460
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.938 |
| 2 | BS_063ERW0R | pilocytic astrocytoma | — | 0.934 |
| 3 | TCGA-XF-A9SH-01A-11R-A39I-07 | — | — | 0.921 |
| 4 | BS_C80S5N37 | EPN | EPN Tumor | 0.915 |
| 5 | BS_JXNZYGCR | DNET | — | 0.914 |
| 6 | BS_K5802F84 | pilocytic astrocytoma | — | 0.912 |
| 7 | TCGA-55-8616-01A-11R-2403-07 | — | cohortA1 | 0.911 |
| 8 | BS_9F09XV62 | low-grade glioma | — | 0.909 |
| 9 | BS_CQSAJ7BF | DNET | — | 0.909 |
| 10 | TCGA-97-A4M1-01A-11R-A24X-07 | — | cohortA1 | 0.908 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.380 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |